期刊
CURRENT RHEUMATOLOGY REPORTS
卷 14, 期 4, 页码 303-309出版社
SPRINGER
DOI: 10.1007/s11926-012-0254-6
关键词
APRIL; Atacicept; BCMA; Belimumab; Blisbimod (A-623); BLyS/BAFF; BR3; Systemic lupus erythematosus; Tabalumab (LY2127399); TACI; SLE
类别
For the first time in more than 50 years, the US Food and Drug Administration has approved a drug specifically for the treatment of systemic lupus erythematosus (SLE). This drug, belimumab, is a monoclonal antibody that neutralizes the B-cell survival factor, B-lymphocyte stimulator (BLyS). Although belimumab has demonstrated a very favorable safety profile, many SLE patients have failed to clinically improve from belimumab therapy. Three additional BLyS antagonists (atacicept, blisibimod, tabalumab) are currently undergoing clinical testing. These antagonists subtly differ from belimumab in their biologic targets, and each is administered through a route (subcutaneous) that differs from the route through which belimumab is currently delivered (intravenous). Whether these differences will have meaningful consequences for efficacy and safety remains to be determined.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据